AMT HOLDING
Identification
Symbol
AMT
ISIN code
NL0000886968
Trading location
Amsterdam
ICB
Pharmaceuticals&Biotechnology
Activity description
Amsterdam Molecular Therapeutics (AMT) Holding B.V. is a biopharmaceutical company that develops gene-based therapies for orphan diseases.
Website address
http://www.amtbv.com
Issuer website
http://www.amtbv.com
Operation
IPO date
Mi. 20/06/2007
IPO type
Initial Public Offering
IPO type
Initial Public offering
Catégorie
IPO
Operation description
Offering of up to 5,000,000 new ordinary shares.
Operation calendar
Trading on Eurolist by Euronext is expected to commence on or about 20 June 2007. Settlement date is the third business day following the listing date, expected to be on or about 25 June 2007
Price range
Between €8.00 and €10.00 per offer share.
Company profile
AMT (Amsterdam Molecular Therapics) specializes in developing of gene therapy products. Those products are for treating serious, often rare, diseases with a major medical need. The group's products are based on the integration of genes in the target organs and tissues to modify the long term gene expression and to correct the genetic defects causing the disease.
AMT has a portfolio of 6 products: 4 in advanced stage preclinical development (Parkinson disease, Duchenne myopathy, Porphyria and Sanfilippo disease treatment), 1 in Phases I/II clinical study (Hemophilia B treatment) and 1 in marketing phase (Glybera® for treating lipoprotein lipase deficiency).
Source:
Cofisem
-
Last Update:
22 Mar 2013
Key Executives
| Official Liquidator | Jörn Aldag | ||||
| Official Liquidator | Piers Morgan | ||||
| Investor Relations | Aicha Diba | ||||
| Source: Cofisem - Last Update: 10 Apr 2012 | |||||
Key figures
| Millenium | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|
| Net sales | |||||
| Income from ordinary activities | 2.192 | 1.448 | 355 | 223 | |
| Operating income | -17.116 | -19.069 | -17.799 | -18.790 | -14.660 |
| Cost of net financial indebtedness | -366 | -142 | 624 | 1.871 | -275 |
| Equity-Accounted companies' contribution to results | |||||
| Net profit from discontinued activities | 0 | ||||
| Net income | -17.300 | -19.118 | -17.175 | -16.919 | -14.935 |
| Net income (group share) | -17.300 | -19.118 | -17.175 | -16.919 | -14.935 |
| Fiscal year end | 12,11 | 12,10 | 12,09 | 12,08 | 12,07 |
| Length of fiscal year (month) | 12 | 12 | 12 | 12 | 12 |
| Currency & Unit | EUR - thousands | EUR - thousands | EUR - thousands | EUR - thousands | EUR - thousands |
| Account Standards | Exercices aux normes IAS-IFRS à compter de l'exercice 2004. | Exercices aux normes IAS-IFRS à compter de l'exercice 2004. | Exercices aux normes IAS-IFRS à compter de l'exercice 2004. | Exercices aux normes IAS-IFRS à compter de l'exercice 2004. | Exercices aux normes IAS-IFRS à compter de l'exercice 2004. |
| Source: Cofisem - Last Update: 22 Mar 2013 | |||||